{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:59:05Z","timestamp":1785185945550,"version":"3.55.0"},"reference-count":39,"publisher":"American Chemical Society (ACS)","issue":"24","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["202510316015Z"],"award-info":[{"award-number":["202510316015Z"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M713482"],"award-info":[{"award-number":["2022M713482"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173672"],"award-info":[{"award-number":["82173672"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173679"],"award-info":[{"award-number":["82173679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204188"],"award-info":[{"award-number":["82204188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the clinical success of tropomyosin receptor kinases (TRKs) inhibitors in NTRK fusion\u2013positive cancers, prolonged administration has resulted in acquired resistance, particularly xDFG mutations, for which no approved therapies are available. Herein, we first presented a series of bifunctional agents as potent TRK inhibitors and degraders featuring a novel 5-amino-4-carbamoylpyrazole scaffold. The representative compounds 19 and 20 demonstrated potent antiproliferative activities against Ba\/F3-LMNA-NTRK1G667C cells with IC50 values of 0.29 and 2.48 nM, respectively, and induced pronounced TRKA G667C degradation (DC50 = 5.86 and 24.69 nM; Dmax &amp;gt; 90%), while sparing the wild-type protein. Further in vivo assay displayed that 20 effectively inhibited tumor growth with no apparent toxicity in the Ba\/F3-LMNA-NTRK1G667C xenograft model. Overall, these findings indicated that, unlike conventional inhibitors, such bifunctional agents represent the first class of monovalent small molecules capable of effectively degrading TRK xDFG mutants, providing valuable insights into overcoming TRK xDFG\u2013mediated clinical resistance.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02491","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:50:57Z","timestamp":1764910257000},"page":"26383-26404","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of Novel\nBifunctional Agents as Potent TRK\nInhibitors and Degraders against xDFG Mutation Resistance"],"prefix":"10.1021","volume":"68","author":[{"given":"Jian","family":"Song","sequence":"first","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjie","family":"Zhu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Zhu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Feng","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Fan","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Mei","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiren","family":"Shi","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhuo","family":"Yang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Feng","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"ORxes Therapeutics Co., Ltd. , ,","place":["Shanghai, China, 200120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianduanyi","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Helsinki , , ,","place":["Helsinki, Finland, FI-00290"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtao","family":"Xu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-0402","authenticated-orcid":true,"given":"Jinyi","family":"Xu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajian","family":"Zhu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"7","key":"2026072715483176800_cit1","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","article-title":"TRK Fusions\nAre Enriched in Cancers with Uncommon Histologies and the Absence\nof Canonical Driver Mutations","volume":"26","author":"Rosen","year":"2020","journal-title":"Clin. Cancer\nRes."},{"issue":"1","key":"2026072715483176800_cit2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cell.2019.02.049","article-title":"A Tumor-Agnostic NTRK (TRK) Inhibitor","volume":"177","author":"Huang","year":"2019","journal-title":"Cell"},{"issue":"4","key":"2026072715483176800_cit3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","article-title":"Insights\ninto Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development\nand Clinical Application","volume":"62","author":"Yan","year":"2019","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026072715483176800_cit4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK Fusion-Positive Cancers and\nTRK Inhibitor Therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026072715483176800_cit5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK Family Proteins in Cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"2026072715483176800_cit6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK Proteins\nin Clinical Cancer Therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"issue":"2","key":"2026072715483176800_cit7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib:\nFirst Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"13","key":"2026072715483176800_cit8","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: First\nGlobal Approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"issue":"suppl_8","key":"2026072715483176800_cit9","doi-asserted-by":"publisher","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK Inhibitors\nin TRK Fusion-Positive Cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"2026072715483176800_cit10","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1535-7163.MCT-16-0909","article-title":"Mechanisms of Resistance\nto NTRK Inhibitors and Therapeutic\nStrategies in NTRK1-Rearranged Cancers","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol.\nCancer Ther."},{"issue":"1","key":"2026072715483176800_cit11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.cd-15-0940","article-title":"Acquired Resistance to the TRK Inhibitor\nEntrectinib in Colorectal Cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discovery"},{"issue":"9","key":"2026072715483176800_cit12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A Next-Generation\nTRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase\nInhibition in Patients with TRK Fusion-Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discovery"},{"issue":"10","key":"2026072715483176800_cit13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.cd-18-0484","article-title":"Repotrectinib\n(TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK\nInhibitor that Potently Inhibits ROS1\/TRK\/ALK Solvent-Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discovery"},{"key":"2026072715483176800_cit14","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/S0959-8049(16)33029-5","article-title":"The Development of LOXO-195, a Second\nGeneration TRK Kinase Inhibitor that Overcomes Acquired Resistance\nto 1st Generation Inhibitors Observed in Patients with TRK-Fusion\nCancers","volume":"69","author":"Blake","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"2026072715483176800_cit15","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery\nof the First Highly Selective and Broadly Effective Macrocycle-Based\nType II TRK Inhibitors that Overcome Clinically Acquired Resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"14","key":"2026072715483176800_cit16","doi-asserted-by":"publisher","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the Next-Generation\nPan-TRK Kinase Inhibitors\nfor the Treatment of Cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072715483176800_cit17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1158\/2159-8290.CD-20-0571","article-title":"TRK xDFG Mutations Trigger a Sensitivity\nSwitch from Type I to II Kinase Inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discovery"},{"issue":"12","key":"2026072715483176800_cit18","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1158\/1535-7163.MCT-21-0632","article-title":"Molecular\nCharacteristics of Repotrectinib That Enable Potent Inhibition of\nTRK Fusion Proteins and Resistant Mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"2026072715483176800_cit19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.apsb.2023.11.010","article-title":"Selective Type II TRK\nInhibitors Overcome xDFG Mutation Mediated\nAcquired Resistance to the Second-Generation Inhibitors Selitrectinib\nand Repotrectinib","volume":"14","author":"Xiang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"2026072715483176800_cit20","doi-asserted-by":"publisher","first-page":"11484","DOI":"10.1021\/acs.jmedchem.5c00412","article-title":"Structural Optimization of Next-Generation\nTRK Inhibitors against Acquired Drug Resistance Mutations for the\nTreatment of Solid Tumors","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026072715483176800_cit21","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1021\/acs.jmedchem.1c01597","article-title":"Structural Optimization and Structure-Activity\nRelationship Studies of 6,6-Dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one\nDerivatives as A New Class of Potent Inhibitors of Pan-Trk and Their\nDrug-Resistant Mutants","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"20","key":"2026072715483176800_cit22","doi-asserted-by":"publisher","first-page":"15503","DOI":"10.1021\/acs.jmedchem.1c01539","article-title":"Discovery of Next-Generation Tropomyosin\nReceptor Kinase Inhibitors for Combating Multiple Resistance Associated\nwith Protein Mutation","volume":"64","author":"Zhuo","year":"2021","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026072715483176800_cit23","doi-asserted-by":"publisher","first-page":"14562","DOI":"10.1021\/acs.jmedchem.0c01342","article-title":"Discovery of First-In-Class\nPotent and Selective Tropomyosin Receptor Kinase Degraders","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"issue":"34","key":"2026072715483176800_cit24","doi-asserted-by":"publisher","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-Selective\nAllosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant\nMutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem., Int. Ed."},{"issue":"26","key":"2026072715483176800_cit25","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance\nMutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated\nDegradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"issue":"5","key":"2026072715483176800_cit26","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, Synthesis,\nand Biological Evaluation of Bcr-Abl PROTACs to Overcome T315I Mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"16","key":"2026072715483176800_cit27","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1021\/acs.jmedchem.2c00681","article-title":"Discovery\nof a Novel\nVascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs\nwith Potent Antitumor Effects","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026072715483176800_cit28","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202421713","article-title":"In Vivo Self-Assembly\nof PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy","volume":"64","author":"Xie","year":"2025","journal-title":"Angew. Chem., Int. Ed."},{"issue":"13","key":"2026072715483176800_cit29","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202217246","article-title":"Discovery of Norbornene as a Novel\nHydrophobic Tag Applied in Protein Degradation","volume":"62","author":"Xie","year":"2023","journal-title":"Angew. Chem., Int. Ed."},{"issue":"7","key":"2026072715483176800_cit30","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1021\/acs.jmedchem.3c00058","article-title":"Discovery\nof a Novel, Potent, Orally\nActive, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026072715483176800_cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115881","article-title":"Design,\nSynthesis and Biological Evaluation of Novel Dihydroquinolin-4(1H)-One\nDerivatives as Novel Tubulin Polymerization Inhibitors","volume":"262","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026072715483176800_cit32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113316","article-title":"Discovery\nof Novel N-Benzylbenzamide Derivatives as Tubulin Polymerization Inhibitors\nwith Potent Antitumor Activities","volume":"216","author":"Zhu","year":"2021","journal-title":"Eur. J. Med.\nChem."},{"issue":"2","key":"2026072715483176800_cit33","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1021\/acs.jmedchem.3c01645","article-title":"Discovery,\nOptimization, and Evaluation of Novel Pyridin-2(1H)-one\nAnalogues as Potent TRK Inhibitors for Cancer Treatment","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026072715483176800_cit34","doi-asserted-by":"publisher","first-page":"12427","DOI":"10.1021\/acs.jmedchem.2c01099","article-title":"Discovery of CH7057288 as an Orally\nBioavailable, Selective,\nand Potent pan-TRK Inhibitor","volume":"65","author":"Ito","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026072715483176800_cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115618","article-title":"Recent Advances in the Discovery of Tropomyosin Receptor\nKinases TRKs Inhibitors: A Mini Review","volume":"258","author":"El-Nassan","year":"2023","journal-title":"Eur.\nJ. Med. Chem."},{"issue":"7239","key":"2026072715483176800_cit36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An Inhibitor\nof NEDD8-activating Enzyme as a New Approach to Treat Cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"issue":"4","key":"2026072715483176800_cit37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymeth.2005.11.007","article-title":"Western Blotting","volume":"38","author":"Kurien","year":"2006","journal-title":"Methods"},{"issue":"1","key":"2026072715483176800_cit38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44391-9","article-title":"FOXP3+ Regulatory\nT cell Perturbation Mediated by the IFN\u03b3-STAT1-IFITM3 Feedback\nLoop is Essential for Anti-tumor Immunity","volume":"15","author":"Liu","year":"2024","journal-title":"Nat.\nCommun."},{"issue":"1","key":"2026072715483176800_cit39","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01248-9","article-title":"Blockade of\nNMT1 Enzymatic Activity\nInhibits N-myristoylation of VILIP3 Protein and Suppresses Liver Cancer\nProgression","volume":"8","author":"Tan","year":"2023","journal-title":"Signal Transduction Targeted Ther."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02491","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/24\/26383\/66291085\/acs.jmedchem.5c02491.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/24\/26383\/66291085\/acs.jmedchem.5c02491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:07:32Z","timestamp":1785182852000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/24\/26383\/5234609\/Discovery-of-Novel-Bifunctional-Agents-as-Potent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":39,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12,25]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02491","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}